Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AEMD | NASDAQ | USD | Real-time | |
0A6R | London | EUR | Real-time | |
EJU0 | TradeGate | EUR | Delayed |
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Edward G. Broenniman | 86 | 1999 | Independent Chairman of the Board |
Geert Schmid-Schönbein | - | - | Member of Sepsis & Inflammation Advisory Board |
Stephen Z. Fadem | - | - | Member of Extracorporeal Therapy Advisory Board |
Nicolas Gikakis | 57 | 2023 | Independent Director |
Nathan W. Levin | - | - | Member of Extracorporeal Therapy Advisory Board |
Larry D. Cowgill | - | - | Member of Sepsis & Inflammation Advisory Board |
Gregory T. A. Kovacs | - | - | Member of Extracorporeal Therapy Advisory Board |
Irshad H. Chaudry | - | - | Member of Sepsis & Inflammation Advisory Board |
David M. Ward | - | - | Member of Extracorporeal Therapy Advisory Board |
Claudio Ronco | - | - | Member of Extracorporeal Therapy Advisory Board |
John A. Kellum | - | - | Member of Extracorporeal Therapy Advisory Board |
Chetan S. Shah | 54 | 2013 | Independent Director |
Angela Rossetti | 70 | 2022 | Independent Director |
Charles J. Fisher | 76 | 2017 | Member of Extracorporeal Therapy Advisory Board |
James B. Frakes | 67 | 2008 | Interim CEO, CFO, Secretary & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review